

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of listing of claims, and listing of claims in the application.

1- 31 (Cancelled)

32. (Previously presented) A monomeric single-chain Fv (scFv) antibody fragment consisting of an amino acid sequence as set forth in SEQ ID NO: 16, wherein the monomeric scFv antibody fragment is specific for human carcinoembryonic antigen.
33. (Previously presented) An antibody fragment according to claim 32, further comprising a detectable agent.
34. (Previously presented) An antibody fragment according to claim 33, wherein the detectable agent is a radioactive label.
35. (Previously presented) An antibody fragment according to claim 33, wherein the detectable agent is a reporter molecule.
36. (Previously presented) A pharmaceutical composition consisting of an amino acid sequence as set forth in SEQ ID NO: 16 and a pharmaceutically-acceptable carrier.
37. (Canceled)
38. (Canceled)
39. (Previously presented) A divalent single-chain Fv (scFv) antibody fragment consisting of an amino acid sequence as set forth in SEQ ID NO: 17, wherein the divalent scFv antibody fragment is specific for human carcinoembryonic antigen.

40. (Previously presented) An antibody fragment according to claim 38, further comprising a detectable agent.
41. (Previously presented) An antibody fragment according to claim 39, wherein the detectable agent is a radioactive label.
42. (Previously presented) An antibody fragment according to claim 39, wherein the detectable agent is a reporter molecule.
43. (Previously presented) A pharmaceutical composition comprising an amino acid sequence as set forth in SEQ ID NO: 17 and a pharmaceutically-acceptable carrier.
44. (Canceled)
45. (Canceled)
46. (Canceled)
47. (New) A monomeric single-chain Fv (scFv) antibody fragment comprising an amino acid sequence as set forth in SEQ ID NO: 16, wherein the monomeric scFv antibody fragment is specific for human carcinoembryonic antigen.
48. (New) An antibody fragment according to claim 47, further comprising a detectable agent.
49. (New) An antibody fragment according to claim 48, wherein the detectable agent is a radioactive label.

- 50. (New) An antibody fragment according to claim 48, wherein the detectable agent is a reporter molecule.
- 51. (New) A pharmaceutical composition comprising an amino acid sequence as set forth in SEQ ID NO: 16 and a pharmaceutically-acceptable carrier.
- 52. (New) A divalent single-chain Fv (scFv) antibody fragment comprising an amino acid sequence as set forth in SEQ ID NO: 17, wherein the divalent scFv antibody fragment is specific for human carcinoembryonic antigen.
- 53. (New) An antibody fragment according to claim 52, further comprising a detectable agent.
- 54. (New) An antibody fragment according to claim 53, wherein the detectable agent is a radioactive label.
- 55. (New) An antibody fragment according to claim 53, wherein the detectable agent is a reporter molecule.
- 56. (New) A pharmaceutical composition comprising an amino acid sequence as set forth in SEQ ID NO: 17 and a pharmaceutically-acceptable carrier.